Mitochondrial dysfunction is the main cause of damage to the pathological mechanism of
ischemic cardiomyopathy. In addition, mitochondrial dysfunction can also affect the …

The mitochondrion is also a major site for maintaining redox homeostasis between reactive
oxygen species (ROS) generation and scavenging. The quantity, quality, and functional …

Myocardial ischemia-reperfusion (MI/R) injury is common in patients who undergo
revascularization therapy for myocardial infarction, often leading to cardiac dysfunction …

Background Although the development of therapies for heart failure (HF) continues apace,
clinical outcomes are often far from ideal. Unc51-like-kinase 1 (ULK1)-mediated mitophagy …

Carfilzomib (CFZ) is a proteasome inhibitor approved for relapsed/refractory multiple
myeloma (MM) but its clinical use is limited by cardiovascular toxicity. The mechanisms of …

The specific mechanism of sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure
(HF) needs to be elucidated. In this study, we use SGLT2-global-knockout (KO) mice to …

Vascular aging, early vascular aging or supernormal vascular aging are concepts used for
estimating the cardiovascular risk at a certain age. From the famous line of Thomas …

Besides structural alterations in the myocardium, heart failure with preserved ejection
fraction (HFpEF) is also associated with molecular and physiological alterations of the …

Objectives Cardiorenal syndrome type-3 (CRS-3) is an abrupt worsening of cardiac function
secondary to acute kidney injury. Mitochondrial dysfunction is a key pathological mechanism …

Sodium-glucose cotransporter inhibitor/inhibition (SGLTi), initially approved as a glucose-
lowering therapy for type 2 diabetes, is associated with decreased risks for many of the most …